Anteris Technologies Global (NASDAQ:AVR) Stock Keeps "Overweight" Rating at Cantor Fitzgerald

Anteris Technologies Global (NASDAQ:AVR - Get Free Report)'s stock had its "overweight" rating restated by equities researchers at Cantor Fitzgerald in a research report issued on Wednesday, Benzinga reports. They currently have a $15.00 price target on the stock. Cantor Fitzgerald's price target points to a potential upside of 132.56% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Weiss Ratings restated a "sell (d-)" rating on shares of Anteris Technologies Global in a research note on Wednesday, August 26th. Barclays upgraded Anteris Technologies Global to a "hold" rating in a research note on Wednesday, October 7th. Three equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Anteris Technologies Global has a consensus rating of "Hold" and an average target price of $14.00.

Anteris Technologies Global Price Performance

NASDAQ AVR opened at $6.45 on Wednesday. The company has a fifty day moving average price of $8.32 and a 200-day moving average price of $8.05. The firm has a market cap of $628.62 million, a price-to-earnings ratio of -3.31 and a beta of 1.87. Anteris Technologies Global has a 1 year low of $3.30 and a 1 year high of $11.06.

Anteris Technologies Global (NASDAQ:AVR - Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to analysts' expectations of $1.50 million. Anteris Technologies Global had a negative net margin of 4,619.27% and a negative return on equity of 77.69%. During the same quarter in the prior year, the company earned ($0.58) EPS. On average, research analysts anticipate that Anteris Technologies Global will post -1.21 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder L1 Capital Pty Ltd purchased 648,455 shares of Anteris Technologies Global stock in a transaction that occurred on Monday, October 5th. The stock was bought at an average price of $7.51 per share, for a total transaction of $4,869,897.05. Following the completion of the transaction, the insider owned 12,778,380 shares in the company, valued at $95,965,633.80. This represents a 5.35% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders have bought 1,554,730 shares of company stock worth $11,694,513 and have sold 3,008,459 shares worth $25,243,576. Insiders own 4.50% of the company's stock.

Hedge Funds Weigh In On Anteris Technologies Global

Institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new position in Anteris Technologies Global during the second quarter valued at about $78,000. Abel Hall LLC bought a new position in Anteris Technologies Global during the first quarter valued at about $63,000. Bartlett & CO. Wealth Management LLC grew its position in Anteris Technologies Global by 174.5% during the first quarter. Bartlett & CO. Wealth Management LLC now owns 12,900 shares of the company's stock valued at $79,000 after buying an additional 8,200 shares during the period. One68 Global Capital LLC bought a new position in Anteris Technologies Global during the second quarter valued at about $128,000. Finally, J. Derek Lewis & Associates Inc. bought a new position in Anteris Technologies Global during the fourth quarter valued at about $70,000.

About Anteris Technologies Global

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company's lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.